Clinical Trial Update: Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of sorafenib with standard therapy in newly diagnosed adult Core Binding Factor Acute Myeloid Leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Core-binding Factor Acute Myeloid Leukemia

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Status: UNKNOWN